2017.

• Dec.22.2017 R & D

  ONO Submits Supplemental Application of Opdivo® (Nivolumab) for Dosage and Administration of Single Dosing Regimen in Japan for a Partial Change in Approved Items of Manufacturing and Marketing Approval(49 KB)

• Dec.22.2017 R & D

  ONO Submit Supplemental Application of Opdivo® (Nivolumab) for Expanded Use of the Adjuvant Treatment of Melanoma in Japan for a Partial Change in Approved Items of Manufacturing and Marketing Approval(72 KB)

• Dec.22.2017 R & D

  ONO Submits Supplemental Application of Opdivo® (Nivolumab) for Indication of Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma in Japan for a Partial Change in Approved Items of Manufacturing and Marketing Approval(71 KB)

• Dec.21.2017 R & D

  Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease(44 KB)

• Dec.19.2017 Licensing

  ONO enters into Collaboration Agreement with Schrödinger Inc.(40 KB)

• Dec.18.2017 R & D

  U.S. Food and Drug Administration (FDA) Accepts Bristol-Myers Squibb's Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma and Grants Priority Review(61 KB)

• Dec.14.2017 Licensing

  ONO Enters into License Agreement with Bristol-Myers Squibb for Prostaglandin E₂ Receptor Antagonists relating to Immuno-Oncology Programs(43 KB)

• Dec.12.2017 Licensing

  Ono Enters into Collaboration Agreement with Cyclenium Pharma, Inc.(33 KB)

• Dec.06.2017 R & D

  CheckMate -078, a Pivotal, Multinational Phase 3 Opdivo (nivolumab) Lung Cancer Trial with Predominantly Chinese Patients, Stopped Early for Demonstrating Superior Overall Survival(44 KB)

• Dec.01.2017 Sustainability

  Ono Announces Participation in United Nations Global Compact(99 KB)

• Nov.29.2017 R & D

  European Medicines Agency Validates Bristol-Myers Squibb's Type II Variation Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Intermediate- and Poor- Risk Patients with Advanced Renal Cell Carcinoma(43 KB)

• Nov.16.2017 R & D

  Encouraging Response Observed with Opdivo (nivolumab) Plus Investigational IDO1 Inhibitor, BMS-986205, in Heavily Pre-Treated Patients with Advanced Cancers in Phase 1/2a Study CA017-003(67 KB)

• Nov.10.2017 R & D

  Opdivo Plus Yervoy Combination Delivered Overall Survival Benefit Across PD-L1 Expression Levels in Intermediate- and Poor-Risk Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(75 KB)

• Nov.09.2017 Licensing

  ONO announces collaboration with Neurimmune in Neurodegenerative Diseases Field(58 KB)

• Nov.08.2017 R & D

  Opdivo (nivolumab) Demonstrates Superior Three-Year Survival Benefit for Patients with Previously Treated Advanced Renal Cell Carcinoma (RCC)(43 KB)

• Nov.07.2017 R & D

  Opdivo® (Nivolumab) Intravenous Infusion Approved in Taiwan for Expanded Use in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated with Platinum-based Therapy(64 KB)

• Nov.06.2017 Management / Finance

  Announcement on Financial Results for FY2017 2Q

• Oct.31.2017 Management / Finance

  Notice Regarding Completion of Cancellation of Treasury Shares(85 KB)

• Oct.31.2017 R & D

  European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) for Treatment of Patients with Resected High-Risk Advanced Melanoma(43 KB)

• Oct.30.2017 R & D

  Opdivo® (Nivolumab) Intravenous Infusion Approved in Taiwan for Additional Indications of Relapsed or Progressed Classical Hodgkin Lymphoma, Locally Advanced Unresectable or Metastatic Urothelial Carcinoma, and Unresectable or Metastatic Melanoma(65 KB)

• Oct.26.2017 Management / Finance

  Revisions of Consolidated Financial Forecasts(76 KB)

• Oct.25.2017 R & D

  Phase 3 A.R.R.O.W. Study of Once-Weekly Kyprolis® (Carfilzomib) Regimen Meets Primary Endpoint of Progression-Free Survival in Relapsed and Refractory Multiple Myeloma Patients(34 KB)

• Oct.17.2017 R & D

  U.S. Food and Drug Administration (FDA) Accepts Bristol-Myers Squibb's Application for Opdivo (nivolumab) in Patients with Resected High-Risk Advanced Melanoma and Grants Priority Review(43 KB)

• Oct.17.2017 R & D

  Opdivo Alone or Combined with Yervoy Shows Encouraging Response and Survival Rates in Recurrent Small Cell Lung Cancer Patients with High Tumor Mutation Burden, in Exploratory Analysis from Phase 1/2 Study CheckMate -032(43 KB)

• Oct.12.2017 Licensing

  Ono Enters into Exclusive License Agreement with Karyopharm to Develop and Commercialize Selinexor and KPT-8602, XPO1 Inhibitors(76 KB)

• Oct.02.2017 Management / Finance

  Notice of Completion of Acquisition of Own Shares(89 KB)

• Sep.29.2017 R & D

  ONO and BMSKK Submit Supplemental Application for Opdivo® (Nivolumab) and Yervoy® (Ipilimumab) Combination Therapy for Unresctable Melanoma in Japan(51 KB)

• Sep.28.2017 R & D

  Ono and Seikagaku Announce Initiation of a Late-Stage Phase II Clinical Trial of SI-613 for Treatment of Enthesopathy(96 KB)

• Sep.27.2017 R & D

  Bristol-Myers Squibb's Opdivo® (nivolumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Previously Treated with Sorafenib(44 KB)

• Sep.22.2017 R & D

  ONO Receives Approval for OPDIVO® (Nivolumab) Intravenous Infusion for Treatment of Unresectable Advanced or Recurrent Gastric Cancer which Has Progressed after Chemotherapy as a Partial Change in Approved Items of Manufacturing and Marketing Approval in Japan(81 KB)

• Sep.20.2017 R & D

  Opdivo® (Nivolumab) Intravenous Infusion Approved for Expanded Use in Advanced Non-squamous Non-small Cell Lung Cancer which Has Been Previously Treated with Platinum-based Therapy in Taiwan(64 KB)

• Sep.19.2017 R & D

  Opdivo® (Nivolumab) Intravenous Infusion Approved for Expanded Use in Unresectable or Metastatic Melanoma in South Korea(40 KB)

• Sep.14.2017 R & D

  Array BioPharma Announces FDA Acceptance for Review of Binimetinib and Encorafenib New Drug Applications for Patients with Advanced BRAF-mutant Melanoma(31 KB)

• Sep.13.2017 R & D

  Phase 3 COLUMBUS Part 2 Results in BRAF-Mutant Melanoma Presented at European Society for Medical Oncology Congress(30 KB)

• Sep.13.2017 R & D

  Phase 3 BEACON CRC Safety Lead-In Results in BRAF-Mutant Colorectal Cancer Presented at European Society for Medical Oncology Congress(30 KB)

• Sep.12.2017 R & D

  Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival and Showed Durable Responses in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma in Phase 3 CheckMate -214 Trial(44 KB)

• Sep.11.2017 R & D

  Opdivo (nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) for Patients with Resected High-Risk Melanoma in Phase 3 CheckMate -238 Study(44 KB)

• Sep.11.2017 R & D

  Two Pivotal Opdivo (nivolumab) Trials Show Three-Year Survival Benefit in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer(62 KB)

• Sep.08.2017 Licensing

  CONCLUSION OF DEVELOPMENT COLLABORATION AGREEMENT FOR OPDIVO® (NIVOLUMAB) AND LENVIMA® (LENVATINIB MESYLATE) COMBINATION THERAPY FOR TREATMENT OF HEPATOCELLULAR CARCINOMA(121 KB)

• Sep.08.2017 R & D

  CheckMate -214 Study Evaluating Opdivo in Combination with Yervoy Stopped Early for Demonstrating Overall Survival Benefit in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(43 KB)

• Sep.01.2017 Licensing

  Ono and Seikagaku Reach a Definitive Agreement Related to Co-development and Marketing Collaboration on SI-613 for the Treatment of Osteoarthritis in Japan(47 KB)

• Sep.01.2017 Management / Finance

  Ono Pharmaceutical Announces Status of Acquisition of Own Shares(146 KB)

• Sep.01.2017 R & D

  Long-Term Analysis of Phase 3 Head-To-Head Study Confirms KYPROLIS® (Carfilzomib) Regimen Extends Overall Survival in Patients with Relapsed Multiple Myeloma(35 KB)

• Aug.30.2017 R & D

  Opdivo® (Nivolumab) Intravenous Infusion Approved for Supplemental Indications of Advanced Renal Cell Carcinoma, Relapsed or Progressed Classical Hodgkin Lymphoma, Recurrent or Metastatic Head and Neck, Locally Advanced or Metastatic Urothelial Carcinoma, and Unresectable or Metastatic Melanoma in Combination with Ipilimumab in South Korea(64 KB)

• Aug.16.2017 R & D

  Bristol-Myers Squibb Announces Topline Results from CheckMate -214, a Phase 3 Study of Opdivo in Combination with Yervoy in Intermediate and Poor-Risk Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(44 KB)

• Aug.16.2017 R & D

  Opdivo® (Nivolumab) Intravenous Infusion Approved for Supplemental Indication of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck with Disease Progression on or after Platinum-based Therapy in Taiwan(73 KB)

• Aug.03.2017 R & D

  Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in MSI-H or dMMR Metastatic Colorectal Cancer That Has Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin, and Irinotecan(45 KB)

• Aug.02.2017 Management / Finance

  Announcement on Financial Results for FY2017 1Q

• Aug.01.2017 Management / Finance

  Ono Pharmaceutical Announces Status of Acquisition of Own Shares(146 KB)

• Jul.18.2017 Sustainability

  Support for Relief Efforts to the Northern Kyushu Heavy Rain(34 KB)

• Jul.14.2017 Management / Finance

  Notice Concerning Determination of Details of Issuance of Stock Options (Stock Acquisition Rights)(90 KB)

• Jul.13.2017 R & D

  Second Phase III Study Shows Kyprolis® (Carfilzomib) Regimen Significantly Improves Overall Survival in Patients with Relapsed Multiple Myeloma(35 KB)

• Jul.06.2017 R & D

  Array BioPharma Submits New Drug Applications to FDA for Binimetinib and Encorafenib in Advanced Melanoma(30 KB)

• Jul.06.2017 R & D

  Phase 3 Study Evaluating the Safety and Efficacy of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint(43 KB)

• Jul.03.2017 Management / Finance

  Ono Pharmaceutical Announces Status of Acquisition of Own Shares(146 KB)

• Jun.29.2017 Management / Finance

  Notice Concerning Issuance of Stock Options (Stock Acquisition Rights)(207 KB)

• Jun.19.2017 R & D

  Extended Follow-Up Data Evaluating Opdivo (nivolumab) Shows Durable Response in Adult Patients with Relapsed or Progressed Classical Hodgkin Lymphoma(134 KB)

• Jun.13.2017 Management / Finance

  Announcement on Acquisition and Retirement of Own Shares(91 KB)

• Jun.05.2017 R & D

  Opdivo (nivolumab) Data in Patients with Advanced Cervical, Vaginal and Vulvar Cancers from Phase 1/2 CheckMate -358 Presented at ASCO(176 KB)

• Jun.05.2017 R & D

  Anti-LAG-3 (BMS-986016) in Combination with Opdivo (nivolumab) Showed Activity in Patients with Melanoma Who Were Relapsed or Refractory to Anti-PD-1/PD-L1 Therapy(171 KB)

• Jun.05.2017 R & D

  Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrated Promising Activity in Previously Treated Patients with dMMR or MSI-H Metastatic Colorectal Cancer in Phase 2 CheckMate -142 Study(177 KB)

• Jun.05.2017 R & D

  First Presentation of Efficacy Data from CheckMate -204 Evaluating the Combination of Opdivo (nivolumab) and Yervoy (ipilimumab) Demonstrates Anti-tumor Activity in Advanced Melanoma Patients with Brain Metastases(164 KB)

• Jun.05.2017 R & D

  European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab) for Previously Treated Locally Advanced Unresectable or Metastatic Urothelial Carcinoma in Adults After Failure of Prior Platinum-Containing Therapy(181 KB)

• May.31.2017 Licensing

  ONO Concludes a License Agreement with Array Biopharma related to Binimetinib, a MEK inhibitor and Encorafenib, a BRAF inhibitor(58 KB)

• May.25.2017 R & D

  U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb's Application for Opdivo (nivolumab) in Previously Treated Hepatocellular Carcinoma(150 KB)

• May.18.2017 R & D

  ONO Receives Supplemental Manufacturing and Marketing Approval of KYPROLIS® for Intravenous Injection 10 mg and 40 mg, a Proteasome Inhibitor, in Relapsed or Refractory Multiple Myeloma(65 KB)

• May.12.2017 Licensing

  Seikagaku and Ono Reach a Basic Agreement Related to Co-development and Marketing Collaboration on SI-613 for the Treatment of Osteoarthritis in Japan(46 KB)

• May.11.2017 Management / Finance

  Announcement on Financial Results for FY2016

• May.11.2017 Management / Finance

  Notice regarding Differences between Non-consolidated Results for the Fiscal year Ended March 31, 2017 and those for the Previous Fiscal Year(55 KB)

• May.08.2017 R & D

  European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for Squamous Cell Cancer of the Head and Neck in Adults Progressing On or After Platinum-based Therapy(188 KB)

• Apr.28.2017 R & D

  OPDIVO® (Nivolumab) Intravenous Infusion Approved for Supplemental Indication of Advanced Renal Cell Carcinoma Who Have Received Prior Anti-angiogenic Therapy in Taiwan(48 KB)

• Apr.28.2017 Corporate

  Announcement on Candidates of Members of the Board of Directors and Corporate Officers(85 KB)

• Apr.24.2017 R & D

  Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) for the Treatment of Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer(145 KB)

• Apr.24.2017 R & D

  Opdivo® (nivolumab) Designated for the Treatment of Biliary Tract Cancer Under the SAKIGAKE Designation System(41 KB)

• Apr.20.2017 Sustainability

  Reconstruction Assistance Activities “Operation Slimmer and Healthier” (SUKOYAKARADA DAISAKUSEN) Held in Iwate Prefecture - Recreation with the Athletes or Holding a Lifestyle Seminar -(517 KB)

• Apr.06.2017 R & D

  U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Previously Treated dMMR or MSI-H Metastatic Colorectal Cancer(147 KB)

• Apr.05.2017 R & D

  Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) and Opdivo Monotherapy Significantly Improved Overall Survival Versus Yervoy Alone in Patients with Previously Untreated Advanced Melanoma(156 KB)

• Apr.05.2017 R & D

  Bristol-Myers Squibb Announces Results from CheckMate -143, a Phase 3 Study of Opdivo (nivolumab) in Patients with Glioblastoma Multiforme(122 KB)

• Apr.05.2017 R & D

  Five-Year Survival Observed With Opdivo (nivolumab) in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC), in Phase 1 Study CA209-003(149 KB)

• Mar.30.2017 R & D

  Supplemental Application of Orencia® (Abatacept) Intravenous Injection 250 mg a Selective T-cell Co-stimulation Modulator for Treatment of Juvenile Idiopathic Arthritis for a Partial Change in Approved Items of Manufacturing and Marketing Approval(78 KB)

• Mar.28.2017 R & D

  Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) for the Treatment of Squamous Cell Cancer of the Head and Neck in Adults Progressing on or After Platinum-based Therapy(129 KB)

• Mar.28.2017 Licensing

  ONO Enters into a Research and Option Agreement with Numab(41 KB)

• Mar.24.2017 R & D

  ONO Receives Approval for OPDIVO® (Nivolumab) Intravenous Infusion for Treatment of Recurrent or Metastatic Head and Neck Cancer as a Partial Change in Approved Items of Manufacturing and Marketing Approval in Japan(62 KB)

• Mar.21.2017 Licensing

  Ono Enters into Collaboration Agreement with X-Chem, Inc.(52 KB)

• Mar.02.2017 R & D

  Phase III Head-to-Head Trial Showed KYPROLIS® (Carfilzomib) Significantly Improved Overall Survival Compared to Velcade® (Bortezomib) in Relapsed or Refractory Multiple Myeloma Patients(33 KB)

• Feb.15.2017 Products

  Launch of PARSABIV® Intravenous Injection for Dialysis (Generic Name: Etelcalcetide Hydrochloride), a Calcimimetic Agent, for Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis(64 KB)

• Feb.08.2017 R & D

  U.S. Food and Drug Administration Approves Parsabiv™ (Etelcalcetide) to Treat Secondary Hyperparathyroidism in Adult Patients on Hemodialysis(31 KB)

• Feb.03.2017 R & D

  Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer(178 KB)

• Feb.02.2017 Management / Finance

  Announcement on Financial Results for FY2016 3Q

• Jan.21.2017 Licensing

  Ono Pharmaceutical Company and Bristol-Myers Squibb Enter Settlement and License Agreement with Merck for Anti-PD-1 Antibody Patent Infringement Litigation(79 KB)

• Jan.20.2017 R & D

  Data with OPDIVO® (nivolumab) Intravenous Infusion in Gastric Cancer from Phase III Clinical Study (ONO-4538-12) Presented at 2017 Gastrointestinal Cancer Symposium (ASCO GI 2017)(75 KB)

• Jan.20.2017 R & D

  Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer(134 KB)